Easily one of the biggest trends right now in the field of medicine is the weight loss drug surge. Without attempting to sound cynical, the reality is that the sector enjoys a massive total addressable market. According to Axios, almost 115 million U.S. adults and children are obese. Prior efforts to address this situation have failed, leading to where we are now: a viable ecosystem for weight loss stocks.Now, I’m no doctor and I’m not even going to pretend that I’m in any position to provide medical advice ...

Key TakeawaysTirzepatide, the active ingredient in Eli Lilly's diabetes drug Mounjaro and obesity medication Zepbound, reduced the risk of heart failure outcomes by 38% versus placebo in a Phase 3 trial.Participants also saw a 15.7% reduction in body weight.Eli Lilly plans to submit the study results to the FDA later this year. The active ingredient in Eli Lilly's (LLY) flagship weight-loss drug has a new potential indication: heart failure treatment. Tirzepatide, sold as Mounjaro to treat Type 2 diabetes a ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Eli Lilly (LLY) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 8, 2024, might help the stock move higher if these key numbers are better than expectati ...

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024.Eli Lilly's weight loss drug Zepbound showed benefits in patients with a common type of heart failure and obesity, according to late-stage trial data the company released Thursday. The findings add to mounting evidence that Zepbound and other popular GLP-1 drugs have health benefits beyond promoting weight loss and regulating blood sugar, which could potentially lead to broader insurance c ...

Analyst Estimates for Q2 2024Q1 2024Q2 2023Revenue$9.97 billion$8.77 billion$8.31 billionDiluted EPS$2.65$2.48$1.95Net Income$2.39 billion$2.24 billion$1.76 billion Key Metric: Mounjaro, Zepbound Sales Demand for the weight-loss drugs has boosted the revenue and shares of Eli Lilly along with Ozempic and Wegovy-maker Novo Nordisk (NVO) over the past year, as the companies have increased production capacity to meet demand. In its first-quarter report, Eli Lilly lifted its revenue and profit projections fo ...

Tirzepatide reduced the risk of heart failure outcomes – heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death – by 38% compared to placebo Tirzepatide significantly improved heart failure symptoms and physical limitations Tirzepatide led to 15.7% weight loss in a combined population of people with and without type 2 diabetes  INDIANAPOLIS, Aug. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT ph ...

There's more than one type of worthy opportunity in this space.If your portfolio doesn't have exposure to the biopharma businesses pursuing the development of weight loss medicines, it might be time to consider changing that situation. With an influx of new drugs for sale, and many competitors looking to secure their share of the pie, there's more than one company that could experience dramatic growth in the next few years and beyond.On that note, let's examine one of the segment's leaders that's worth buyi ...

Core Insights - The competition in the anti-obesity medicine market is currently between Novo Nordisk's Wegovy and Eli Lilly's Zepbound, but the dynamics are expected to change significantly by 2030 [1][2] - A report by Evaluate suggests that Novo Nordisk is likely to lead the market for weight loss drugs by 2030, with its candidate CagriSema projected to generate over $20.2 billion in annual revenue [3][4] Company Analysis - Novo Nordisk's CagriSema is expected to outperform Eli Lilly's candidates, with Eli Lilly's orforglipron and retatrutide estimated to generate $8.3 billion and $5 billion respectively, totaling $13.3 billion [4] - CagriSema's unique mechanism of action, utilizing three different physiological levers, may provide a competitive edge over Eli Lilly's drugs, which target fewer receptors [5][6][7] - Eli Lilly currently has a market advantage with Zepbound, which is anticipated to capture a larger market share due to its effectiveness, despite Novo Nordisk's potential long-term success [9] Market Dynamics - The market for weight loss therapies is expected to evolve with multiple players and drug candidates, making it unlikely for one company to dominate entirely [2] - Both companies have the potential for growth, and investing in either or both may be beneficial given the large market opportunity [9]

The stock is up 250% in three years on growth in GLP-1 medications.Weight loss drugs, primarily GLP-1 agonists, have taken the healthcare industry and the stock market by storm. Leading pharmaceutical company Eli Lilly (LLY -2.02%) is a significant player in the space, helping explain why the stock has soared 250% over the past three years.Investors who may want to buy shares have been left wondering if they're too late, or if there's more to Lilly than its headline-grabbing GLP-1 products.So I dove into th ...

Pharma stocks can be strong investments regardless of economic conditions, as this stability arises because the demand for medications and healthcare services remains steady, even when prices rise. Pharmaceutical stocks tend to be more resilient during economic downturns due to steady demand, which is bolstered by the healthcare insurance that covers the cost of most drugs on the market, ensuring a steady supply.This makes them a reliable option for investors looking for stability and picks to carry on thei ...